Lawsuit Information Center

Mounjaro is a diabetes drug manufactured by Eli Lilly. Recently, Mounjaro (and similar drugs like Ozempic and Wegovy) have become widely used for weight loss and weight management in obese patients. New evidence has emerged, however, showing that using higher doses of Mounjaro for weight loss can cause serious health problems involving the gallbladder and the gastrointestinal system. Mounjaro use has been linked to gallbladder disease, gallstones, gastroparesis (stomach paralysis), and other stomach conditions.

Eli Lilly apparently knew about these dangerous risks associated with Mounjaro but failed to warn doctors and patients about them. Individuals who used Mounjaro and suffered some of these injuries are now bringing Mounjaro product liability lawsuits. The national mass tort lawyers at Miller & Zois are investigating new Mounjaro injury cases. If you took Mounjaro for weight loss and suffered gastroparesis, contact us for a free case evaluation. Call us at 800-553-8082. Continue reading

Veozah (fezolinetant), a non-hormonal drug hailed as a breakthrough for managing menopausal hot flashes, was approved by the FDA in May 2023. Marketed as a safe alternative to hormone replacement therapies, Veozah quickly gained popularity among women seeking relief from debilitating vasomotor symptoms. However, the celebration was short-lived. Reports of severe liver injuries linked to the drug began to surface, prompting FDA interventions and spurring a wave of lawsuits.

Patients allege that Veozah’s manufacturer, Astellas Pharma, failed to adequately warn consumers and healthcare providers about the significant risks associated with its use. As the number of affected individuals grows, legal action is shedding light on the dangers of insufficient drug testing and corporate negligence.

Reverse Chronological Timeline of Key Events

In many ways, 2024 was an anti-climatic year in the world of mass torts. The 3M Earplugs settlement has been a disappointment for thousands of claimants. The rejection of J&J’s efforts to force the talc claims into bankruptcy has not prompted a major settlement and the hernia mesh claims continue to drag on. We did get a major global settlement in the AFFF litigation, but it only covered water contamination claims by local municipalities.

Let’s talk about what we can expect in 2025 in the mass tort class action lawsuits with the highest predicted settlement payouts.

Roundup